JP2020525475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020525475A5 JP2020525475A5 JP2019572102A JP2019572102A JP2020525475A5 JP 2020525475 A5 JP2020525475 A5 JP 2020525475A5 JP 2019572102 A JP2019572102 A JP 2019572102A JP 2019572102 A JP2019572102 A JP 2019572102A JP 2020525475 A5 JP2020525475 A5 JP 2020525475A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- acetamide
- trifluoromethyl
- cyano
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 16
- 239000013078 crystal Substances 0.000 claims 13
- -1 5-cyano-pyridin-2-ylmethyl Chemical group 0.000 claims 12
- 238000010586 diagram Methods 0.000 claims 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- LSYANGLAZUZYFX-UHFFFAOYSA-N N-[1-[(5-cyanopyridin-2-yl)methyl]pyrazol-3-yl]-2-[4-[1-(trifluoromethyl)cyclopropyl]phenyl]acetamide Chemical compound C(#N)C=1C=CC(=NC=1)CN1N=C(C=C1)NC(CC1=CC=C(C=C1)C1(CC1)C(F)(F)F)=O LSYANGLAZUZYFX-UHFFFAOYSA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 238000000113 differential scanning calorimetry Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000001757 thermogravimetry curve Methods 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002981 neuropathic effect Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000000646 scanning calorimetry Methods 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023104050A JP2023123679A (ja) | 2017-07-05 | 2023-06-26 | Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセタミドの結晶形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 | ||
| EPPCT/EP2017/066806 | 2017-07-05 | ||
| PCT/EP2018/068087 WO2019008034A1 (en) | 2017-07-05 | 2018-07-04 | CRYSTALLINE FORM OF N- [1- (5-CYANO-PYRIDIN-2-YLMETHYL) -1H-PYRAZOL-3-YL] -2- [4- (1-TRIFLUOROMETHYL-CYCLOPROPYL) -PHENYL] -ACETAMIDE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023104050A Division JP2023123679A (ja) | 2017-07-05 | 2023-06-26 | Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセタミドの結晶形 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020525475A JP2020525475A (ja) | 2020-08-27 |
| JP2020525475A5 true JP2020525475A5 (enExample) | 2021-08-12 |
Family
ID=63079885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572102A Pending JP2020525475A (ja) | 2017-07-05 | 2018-07-04 | Ｎ−［１−（５−シアノ−ピリジン−２−イルメチル）−１ｈ−ピラゾール−３−イル］−２−［４−（１−トリフルオロメチル−シクロプロピル）−フェニル］−アセタミドの結晶形 |
| JP2023104050A Pending JP2023123679A (ja) | 2017-07-05 | 2023-06-26 | Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセタミドの結晶形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023104050A Pending JP2023123679A (ja) | 2017-07-05 | 2023-06-26 | Ｎ－［１－（５－シアノ－ピリジン－２－イルメチル）－１ｈ－ピラゾール－３－イル］－２－［４－（１－トリフルオロメチル－シクロプロピル）－フェニル］－アセタミドの結晶形 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (enExample) |
| EP (1) | EP3649117B1 (enExample) |
| JP (2) | JP2020525475A (enExample) |
| KR (1) | KR102645911B1 (enExample) |
| CN (1) | CN110831932A (enExample) |
| AU (1) | AU2018296423B2 (enExample) |
| BR (1) | BR112020000099A2 (enExample) |
| CA (1) | CA3067489A1 (enExample) |
| CL (1) | CL2020000002A1 (enExample) |
| EA (1) | EA202090193A1 (enExample) |
| IL (1) | IL271764B2 (enExample) |
| MA (1) | MA50972A (enExample) |
| MY (1) | MY206357A (enExample) |
| PH (1) | PH12020500040A1 (enExample) |
| SG (1) | SG11201912881SA (enExample) |
| UA (1) | UA126582C2 (enExample) |
| WO (1) | WO2019008034A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
| US20230047102A1 (en) | 2019-12-20 | 2023-02-16 | Idorsia Pharmaceuticals Ltd | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| CN118202050A (zh) * | 2021-08-17 | 2024-06-14 | 韩国科学技术院 | 靶向cav3.1基因的反义寡核苷酸及其用途 |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015270118C1 (en) | 2014-06-03 | 2019-11-28 | Idorsia Pharmaceuticals Ltd | Pyrazole compounds and their use as T-type calcium channel blockers |
| JP6500092B2 (ja) | 2014-09-15 | 2019-04-10 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｔ型カルシウムチャンネルブロッカーとしてのトリアゾール化合物 |
| TWI808952B (zh) | 2016-12-16 | 2023-07-21 | 瑞士商愛杜西亞製藥有限公司 | 包含t型鈣通道阻斷劑之醫藥組合 |
| CN110234622B (zh) | 2017-02-06 | 2023-07-04 | 爱杜西亚药品有限公司 | 用于合成1-芳基-1-三氟甲基环丙烷的新颖方法 |
| KR102645911B1 (ko) * | 2017-07-05 | 2024-03-08 | 이도르시아 파마슈티컬스 리미티드 | N-[1-(5-시아노-피리딘-2-일메틸)-1h-피라졸-3-일]-2-[4-(1-트리플루오로메틸-시클로프로필)-페닐]-아세타미드의 결정질 형태 |
-
2018
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active Active
- 2018-07-04 EP EP18749304.4A patent/EP3649117B1/en active Active
- 2018-07-04 MY MYPI2020000011A patent/MY206357A/en unknown
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en active Active
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en not_active Ceased
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020525475A5 (enExample) | ||
| JP7057317B2 (ja) | 疾患の治療のための二重機構阻害剤 | |
| DE69431056T2 (de) | Substituierte oxazolyl-derivate zur behandlung von entzündungen | |
| JP5756804B2 (ja) | Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン | |
| EP2927231A1 (en) | Imidazopyridine compounds | |
| JP2015520151A5 (enExample) | ||
| KR101424013B1 (ko) | 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법 | |
| JP5693814B2 (ja) | 新規のヒスタミンｈ３−受容体リガンドおよびそれらの治療的応用 | |
| HK1206339A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| JP6854386B2 (ja) | リゾホスファチジン酸受容体１（ｌｐａｒ１）阻害剤化合物 | |
| JP2014508128A5 (enExample) | ||
| JP5494482B2 (ja) | トリアゾール誘導体またはその塩 | |
| TW200829585A (en) | Cyclohexenyl-aryl compounds for inflammation and immune-related uses | |
| TW201018465A (en) | Heteroaryl antagonists of prostaglandin D2 receptors | |
| JP2002516909A (ja) | 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用 | |
| JP2015520202A (ja) | Ｌｐａｒ拮抗薬としてのｎ−アルキルトリアゾール化合物 | |
| JP2018536687A (ja) | ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト | |
| JP2019535788A5 (enExample) | ||
| CN104411690A (zh) | 作为lpar拮抗剂的取代的吡唑化合物 | |
| JP7664642B2 (ja) | 化合物およびｍｉｆ阻害剤としての用途 | |
| TWI486336B (zh) | 疼痛治療劑 | |
| JP2016510768A5 (enExample) | ||
| RU2017131522A (ru) | (2s,4r)-5-(5'-хлор-2'-фторбифенил-4-ил)-2-этоксиоксалиламино)-)-2-гидроксиметил-2-метилпентановая кислота | |
| CN103917524A (zh) | 双环杂环化合物 | |
| JP2020504165A5 (enExample) |